Emma Morton1, Venkat Bhat2, Peter Giacobbe2, Wendy Lou3, Erin E Michalak4, Shane McInerney2,5, Trisha Chakrabarty4, Benicio N Frey6, Roumen V Milev7, Daniel J Müller2, Sagar V Parikh8, Susan Rotzinger2, Sidney H Kennedy2, Raymond W Lam4. 1. Department of Psychiatry, University of British Columbia, 5950 Wesbrook Mall, Vancouver, BC, V6T 2A1, Canada. emma.morton@ubc.ca. 2. Department of Psychiatry, University of Toronto, Toronto, ON, Canada. 3. Dalla Lane School of Public Health, University of Toronto, Toronto, ON, Canada. 4. Department of Psychiatry, University of British Columbia, 5950 Wesbrook Mall, Vancouver, BC, V6T 2A1, Canada. 5. Department of Psychiatry, National University of Ireland, Galway, Ireland. 6. Department of Psychiatry and Behavioural Neurosciences, McMaster University, Hamilton, ON, Canada. 7. Departments of Psychiatry and Psychology, Queen's University, Kingston, ON, Canada. 8. Department of Psychiatry, University of Michigan, Ann Arbor, MI, USA.
Abstract
BACKGROUND: Non-response to first-line treatment for major depressive disorder (MDD) is common; for such individuals, quality of life (QoL) impairments can be severe. Identifying predictors of QoL changes may support the management of cases with persistent depressive symptoms despite adequate initial pharmacological/psychological treatment. OBJECTIVE: The present study aimed to explore predictors of domain-specific QoL improvement following adjunctive aripiprazole treatment for inadequate response to initial antidepressant therapy. METHODS: We evaluated secondary QoL outcomes from a CAN-BIND (Canadian Biomarker Integration Network in Depression) study in patients with MDD who did not respond to an initial 8 weeks of escitalopram and received a further 8 weeks of adjunctive aripiprazole (n = 96). Physical, psychological, social, and environmental QoL domains were assessed using the World Health Organization QoL Scale Brief Version (WHOQOL-BREF). Clinician-rated depressive symptoms were assessed using the Montgomery-Åsberg Depression Rating Scale (MADRS). Functioning was measured with the Sheehan Disability Scale (SDS). Satisfaction with medication was assessed with a single item from the Quality of Life Enjoyment and Satisfaction Questionnaire Short Form (Q-LES-Q-SF). Exploratory t-tests were used to describe domain score changes. A hierarchical linear regression was used to explore demographic, clinical, and treatment-related predictors of improvement. RESULTS: Across domains, QoL improved with adjunctive aripiprazole treatment. Satisfaction with medication and MADRS and SDS scores similarly improved. Symptom reduction was a predictor for positive change to physical and psychological QoL; functioning improvements were predictive of increases to all QoL domains. Satisfaction with medication predicted improvements to physical and psychological domains, whereas number of medication trials was a predictor of worsening QoL in the physical domain. CONCLUSION: The final model explained the most variance in psychological (68%) and physical (67%) QoL. Less variance was explained for environmental (43%) and social QoL (33%), highlighting a need for further exploration of predictors in these domains. Strategies such as functional remediation may have potential to support QoL for individuals with persistent depressive symptoms. CLINICAL TRIALS REGISTRY: ClinicalTrials.gov identifier: NCT016557.
BACKGROUND: Non-response to first-line treatment for major depressive disorder (MDD) is common; for such individuals, quality of life (QoL) impairments can be severe. Identifying predictors of QoL changes may support the management of cases with persistent depressive symptoms despite adequate initial pharmacological/psychological treatment. OBJECTIVE: The present study aimed to explore predictors of domain-specific QoL improvement following adjunctive aripiprazole treatment for inadequate response to initial antidepressant therapy. METHODS: We evaluated secondary QoL outcomes from a CAN-BIND (Canadian Biomarker Integration Network in Depression) study in patients with MDD who did not respond to an initial 8 weeks of escitalopram and received a further 8 weeks of adjunctive aripiprazole (n = 96). Physical, psychological, social, and environmental QoL domains were assessed using the World Health Organization QoL Scale Brief Version (WHOQOL-BREF). Clinician-rated depressive symptoms were assessed using the Montgomery-Åsberg Depression Rating Scale (MADRS). Functioning was measured with the Sheehan Disability Scale (SDS). Satisfaction with medication was assessed with a single item from the Quality of Life Enjoyment and Satisfaction Questionnaire Short Form (Q-LES-Q-SF). Exploratory t-tests were used to describe domain score changes. A hierarchical linear regression was used to explore demographic, clinical, and treatment-related predictors of improvement. RESULTS: Across domains, QoL improved with adjunctive aripiprazole treatment. Satisfaction with medication and MADRS and SDS scores similarly improved. Symptom reduction was a predictor for positive change to physical and psychological QoL; functioning improvements were predictive of increases to all QoL domains. Satisfaction with medication predicted improvements to physical and psychological domains, whereas number of medication trials was a predictor of worsening QoL in the physical domain. CONCLUSION: The final model explained the most variance in psychological (68%) and physical (67%) QoL. Less variance was explained for environmental (43%) and social QoL (33%), highlighting a need for further exploration of predictors in these domains. Strategies such as functional remediation may have potential to support QoL for individuals with persistent depressive symptoms. CLINICAL TRIALS REGISTRY: ClinicalTrials.gov identifier: NCT016557.
Authors: Mark Zimmerman; Joseph B McGlinchey; Michael A Posternak; Michael Friedman; Naureen Attiullah; Daniela Boerescu Journal: Am J Psychiatry Date: 2006-01 Impact factor: 18.112
Authors: Arne Beck; A Lauren Crain; Leif I Solberg; Jürgen Unützer; Russell E Glasgow; Michael V Maciosek; Robin Whitebird Journal: Ann Fam Med Date: 2011 Jul-Aug Impact factor: 5.166
Authors: A J Ferrari; A J Somerville; A J Baxter; R Norman; S B Patten; T Vos; H A Whiteford Journal: Psychol Med Date: 2012-07-25 Impact factor: 7.723
Authors: Joshua D Rosenblat; Gregory E Simon; Gary S Sachs; Ingrid Deetz; Allen Doederlein; Denisse DePeralta; Mary Mischka Dean; Roger S McIntyre Journal: J Affect Disord Date: 2018-09-12 Impact factor: 4.839